Analysguiden publishes research report setting price target of SEK 30 with an optimistic fair value of SEK 60

Hørsholm, Denmark, June 13, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in June, following the publication of Q1 2022 results, the positive Phase II COVID-19 results for the ABNCoV2 vaccine with respect to omicron protection, and progression of the preclinical-stage breast cancer vaccine candidate ES2B-C001. Analysguiden sets a price target of SEK 30, based on a revised forecast of market size and likelihood of approval, while estimating an optimistic scenario resulting in a fair value of SEK 60.

The research report is available on the Analyst Reports page of ExpreS²ion’s investor website, as well as on Analysguiden’s web-page (at both sites in Swedish and English).

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se
 

For further information about ExpreS²ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About ExpreS2ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS²ion owns 34%. For additional information, please visit www.expres2ionbio.com.